A Monte Carlo simulation approach to the characterization of uncertainties in cancer staging and radiation treatment decisions
暂无分享,去创建一个
P. Dunscombe | E. Ekaette | R. C. Lee | K.-L. Kelly | P. Dunscombe | E. Ekaette | Karie-Lynn Kelly | R. Lee
[1] G J Rosenbusch,et al. [Reliability of sonography in diagnosing liver metastases in breast and bronchial cancer. A retrospective comparison of physical examination, laboratory tests and liver scintigraphy]. , 1986, Ultraschall in der Medizin.
[2] Max Henrion,et al. Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis , 1990 .
[3] B J McNeil,et al. Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison. , 1983, Radiology.
[4] A. Lluch,et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis , 2005, Breast Cancer Research and Treatment.
[5] A. Vecchione,et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. , 1999, Anticancer research.
[6] Gisela del Rocío Estrada Sánchez,et al. Confiabilidad del CA 15-3 como seguimiento en las pacientes con carcinoma mamario y metástasis óseas , 2003 .
[7] L. Frati,et al. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer , 1995, The International journal of biological markers.
[8] S. Yasuda,et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy , 2001, Nuclear medicine communications.
[9] Dino Amadori,et al. Staging of Breast Cancer: New Recommended Standard Procedure , 2002, Breast Cancer Research and Treatment.
[10] J O Prior,et al. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer , 2003, Nuclear medicine communications.
[11] E. Imhoff,et al. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.
[12] J Hermans,et al. Prospective comparative study of ultrasound, CT-scan, scintigraphy and laboratory tests to detect hepatic metastases. , 1991, Journal of nuclear biology and medicine.
[13] A. Fasoli. [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.
[14] B Padovani,et al. Etiologic diagnosis of hepatic lesions in cancer patients. Value of ultrasound and liver function tests. , 1997, Clinical imaging.
[15] Peter Norvig,et al. Artificial Intelligence: A Modern Approach , 1995 .
[16] J Hermans,et al. Hepatic metastases: comparative study of diagnostic ultrasound, CT, nuclear scintigraphy and laboratory tests. , 1991, The Netherlands journal of surgery.
[17] J. Dowie,et al. ‘Evidence-based’, ‘Cost-Effective’ and ‘Preference-Driven’ Medicine: Decision Analysis Based Medical Decision Making is the Pre-Requisite , 1996, Journal of health services research & policy.
[18] T. Mcgarrity,et al. An analysis of imaging studies and liver function tests to detect hepatic neoplasia , 1987, Digestive Diseases and Sciences.
[19] A Spanu,et al. The role of (99m)Tc-tetrofosmin pinhole-SPECT in breast cancer non palpable axillary lymph node metastases detection. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[20] A Pupi,et al. Staging Breast Cancer - Screening for Occult Metastases , 1985, Tumori.
[21] M. Góralczyk,et al. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. , 2001, Przeglad lekarski.
[22] W. Yasmineh,et al. Value of alkaline phosphatase, 5'-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liver. , 1977, Clinical chemistry.
[23] F. J. Davis,et al. Illustration of Sampling‐Based Methods for Uncertainty and Sensitivity Analysis , 2002, Risk analysis : an official publication of the Society for Risk Analysis.
[24] F. Guadagni,et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] Gisela del Rocío Estrada-Sánchez,et al. [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases]. , 2003, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[26] A. Y. Foo,et al. Measurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancer. , 1984, Journal of clinical pathology.
[27] Hans-Jürgen Gallowitsch,et al. F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.
[28] M Torres,et al. CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA , 1995, The International journal of biological markers.
[29] K. Holli,et al. Role of Chest X-ray in Diagnosis of the First Breast Cancer Relapse: A Randomized Trial , 2003, Breast Cancer Research and Treatment.
[30] M. Hou,et al. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. , 1999, The Kaohsiung journal of medical sciences.
[31] Z Kusić,et al. Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. , 1999, Nuclear medicine communications.
[32] C A Williams,et al. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Monica Morrow,et al. Changes in breast cancer therapy because of pathology second opinions , 2002, Annals of Surgical Oncology.
[34] R C Lee,et al. 221 DEVELOPMENT OF HUMAN EXPOSURE-FACTOR DISTRIBUTIONS USING MAXIMUM-ENTROPY INFERENCE , 1995 .
[35] Fiorella Guadagni,et al. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer , 2001, Breast Cancer Research and Treatment.
[36] W. H. M. Schattevoet,et al. Die Zuverlässigkeit der Sonographie bei der Diagnostik von Lebermetastasen beim Mamma- und Bronchialkarzinom , 2008 .
[37] W. D. Bostick,et al. Biological markers as an aid in the clinical management of patients with liver metastases , 1982, Journal of surgical oncology.
[38] R. Sirota,et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome , 2000, Cancer.
[39] G Parmigiani,et al. Measuring uncertainty in complex decision analysis models , 2002, Statistical methods in medical research.
[40] C. Eggers,et al. CANCER OF THE BREAST , 1941, Annals of surgery.
[41] David C. Smith,et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial , 1996, The Lancet.
[42] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .
[43] Norman Wolmark,et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M Untch,et al. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. , 1998, Anticancer research.